Synaptogenix, Inc. SNPX has teamed up with Cannasoul Analytics Ltd. a company founded by the Technion Research & Development Foundation and world-renowned cannabis key opinion leader and researcher Professor Dedi Meiri of The Technion
The New York-based biopharmaceutical company developing therapeutics for neurodegenerative disorders and approximately $33 million in cash as of June 30, 2023, aims to support research and development of pharmaceutical therapeutics.
Under terms of the investment agreement, Synaptogenix obtained a preemptive right to fund the further research and commercialization of certain intellectual property, technology, and future products developed by Cannasoul and licensed from The Technion.
Professor Peretz Lavie, 16th president of the Technion and Cannasoul board member, praised the new collaboration.
See also: Hebrew University, Cannabis Accelerator Collaborate To Advance Medical Marijuana Research
"Cannasoul is pleased to welcome Synaptogenix as a key partner in our development of groundbreaking therapeutics derived from natural compounds,” Lavie said. “Together with Synaptogenix, we look forward to advancing our leadership in developing effective cannabis and psilocybin-based treatments that will be easily accessible to patients worldwide."
Professor Meiri agreed.
“We are very excited to partner with Synaptogenix and believe that Synaptogenix's expertise in pharmaceutical development will enable us to advance development and commercialization of Cannasoul's current intellectual property and engage in new projects based on the exciting research being conducted in my lab at The Technion," Meiri said.
Meiri heads the Laboratory of Cancer Biology and Cannabinoid Research at The Technion's Faculty of Biology. Together with The Technion, Israel's center of applied research, Meiri founded Cannasoul in 2018 for the development of cannabinoid-based and other therapeutics for various indications and vertical markets.
So far, Cannasoul has developed technology in large disease markets including leukemia, epilepsy and sleep disorders.
Now read: Millions Of Dollars For Cannabis Research, Marijuana On The Ballot In Florida & More Pot Reg Updates
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
- 47.10% with $GTBIF
- 40.23% with $TCNNF
- 21.50% with $VFF
Photo: Courtesy of Louis Reed on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!